{
    "clinical_study": {
        "@rank": "23393", 
        "arm_group": [
            {
                "arm_group_label": "CJ-30044", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "TALION TAB. 10mg", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Study objectives\n\n        -  To compare the safety and pharmacokinetic properties of CJ-30044 and bepotastine\n           besylate after a single oral administration in healthy male volunteers.\n\n        -  To evaluate the food-effect on pharmacokinetics of CJ-30044 after a single oral\n           administration in healthy male volunteers."
        }, 
        "brief_title": "A Randomized, Open Label, Three-Treatment, Three-Period, Six-Sequence Crossover Study To Compare Safety and Pharmacokinetic Properties of CJ-30044 and Bepotastine Besilate and To Investigate Food-effect on Pharmacokinetics of CJ-30044 in Healthy Adult Male Volunteers", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male volunteers in the age between 20 and 45 years old\n\n               -  BMI(Body Mass Index) in the range of 18.5 to 25kg/m2\n\n          2. Subject with no history of any significant chronic disease\n\n          3. Judged to be in good health on the basis of their vital sign, ECG, physical exam and\n             routine laboratory data for this trial by investigators\n\n          4. Willing to adhere to protocol requirements and sign a informed consent form\n\n        Exclusion Criteria:\n\n          1. History of clinically significant allergies, including Bepotastine.\n\n          2. History of clinically significant hepatic, renal, neurology, psychiatric, pulmonary,\n             endocrine, hematologic, cardiovascular disease\n\n          3. History of surgery except or gastrointestinal disease which might significantly\n             change absorption of medicines\n\n          4. Subjects considered as unsuitable health on the basis of their vital sign, ECG,\n             physical exam and routine laboratory data for this trial by investigators.\n\n          5. Clinical laboratory test values are outside the accepted normal range\n\n               -  AST or ALT >1.25 times to normal range\n\n               -  Total bilirubin >1.5 times to normal range\n\n          6. Estimated GFR(Glomerular Filtration Rate) < 80 mL/min/1.73m2\n\n          7. Clinically significant vital sign\n\n               -  SBP(Systolic Blood Pressure) \u2264 90 mmHg or SBP \u2265 150 mmHg\n\n               -  DBP(Diastolic Blood Pressure) \u2264 50 mmHg or DBP \u2265 100 mmHg\n\n          8. History of drug abuse or positive urine screen for drugs\n\n          9. History of caffeine, alcohol, smoking abuse\n\n               -  caffeine > 5 cups/day\n\n               -  alcohol > 210g/week\n\n               -  smoking > 10 cigarettes/day\n\n         10. Special diet known to interfere with the absorption, distribution, metabolism or\n             excretion of drugs (especially, consumption of grapefruit juice) within 7 days prior\n             to drug administration\n\n         11. Use of prescription only medicine and oriental medicine within the 14 days before\n             dosing or use of non-prescription medicine within the 7 days before dosing\n\n         12. Participated in a previous clinical trial within 60 days prior to dosing\n\n         13. Donated blood within 60 days prior to dosing\n\n         14. Subjects considered as unsuitable based on medical judgement by investigators"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01925313", 
            "org_study_id": "CJ_BEP_101"
        }, 
        "intervention": [
            {
                "arm_group_label": "CJ-30044", 
                "description": "20.51mg a day,PO,QD", 
                "intervention_name": "CJ-30044", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "TALION TAB. 10mg", 
                "description": "10mg a day,PO,BID", 
                "intervention_name": "TALION TAB. 10mg", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Safety", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "August 15, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Yonsei university severance hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open Label, Three-Treatment, Three-Period, Six-Sequence Crossover Study To Compare Safety and Pharmacokinetic Properties of CJ-30044 and Bepotastine Besilate and To Investigate Food-effect on Pharmacokinetics of CJ-30044 in Healthy Adult Male Volunteers", 
        "overall_official": {
            "affiliation": "yonsei university severance hospital", 
            "last_name": "Min-Su Park, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "AUClast and Peak plasma concentration (Cmax) of Bepotastine", 
            "safety_issue": "No", 
            "time_frame": "Blood sampling up to 36hs post dose."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01925313"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "AUCinf, Tmax, T1/2 of Bepotastine", 
            "safety_issue": "No", 
            "time_frame": "Blood sampleing up to 36hrs post dose"
        }, 
        "source": "CJ HealthCare Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CJ HealthCare Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}